To The Moon

Shares of three biotech stocks, $Viking Therapeutics(VKTX)$ $Skye Bioscience Inc.(SKYE)$ $Janux Therapeutics, Inc.(JANX)$, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri

On Monday, all three major US stock indices gave up their intraday gains and closed in the red. The $S&P 500(.SPX)$ fell 1.2% and below 5,100 points, marking a 2.6% decline over two trading sessions - the steepest drop in more than a year.Additionally, the $DJIA(.DJI)$ dipped 0.7%, and the $NASDAQ(.IXIC)$ tumbled 1.8%, with large-cap tech stocks taking the lead in the sell-off. $Microsoft(MSFT)$ $Apple(AAPL)$ and $NVIDIA Corp(NVDA)$ were among the top losers in the interest rate-sensitive tech sector.Almost all the stocks in the

图片 $Goldman Sachs(GS)$ is taking some profits out of soaring tech stocks and redirecting them towards lower-cost companies. A recent analysis shows that the combined market value of the "Magnificent Seven" has exceeded $13 trillion.Alexandra Wilson-Elizondo, co-chief investment officer of Goldman Sachs Multi-Asset Solutions, said the firm believes tech stocks will be under pressure, and is more optimistic about areas like energy and Japanese stocks. In her view, the US economy is heading towards a soft landing, but there are plenty of risks that could change that trajectory.She added:We love taking profits in tech and moving them to other sectors. In tech, the risk-reward ratio is tipping towards the downside. While we still believe in being long st

图片In the past 12 months, the stock price of $Eli Lilly(LLY)$ has skyrocketed to triple digits, and the most significant driving force behind this surge is weight loss drugs. The weight loss drug market is poised to become a colossal $100 billion industry, and Eli Lilly's two weight loss drugs, Mounjaro and Zepbound, are both expected to become long-term blockbusters.In the weight loss drug market, Eli Lilly and $Novo-Nordisk A/S(NVO)$ still hold the lion's share. But here's the kicker: Eli Lilly is poised to continue dominating this market in the future.First, Mounjaro was approved to treat type 2 diabetes, but doctors often prescribe it as a weight loss drug, and it brought in more than $5 billion in reven

图片It looks like Chinese stocks are on the verge of a rebound, and analysts are finding more reasons to be bullish on them! At the end of March, investment analysts from $Citigroup(C)$ , $Morgan Stanley(MS)$ , and $Bank of America(BAC)$ upgraded their ratings on at least three Chinese stocks: $Tencent Music(TME)$ $Kingsoft Cloud Holdings Ltd(KC)$ $21vianet(VNET)$.Chris Brightman, the chief investment officer of Research Affiliates LLC, a quantitative fund under Pacific Investment Management Co., said that as valuations have become cheaper, we're

图片While $Madrigal Pharmaceuticals(MDGL)$ 's stock price has only gone up about 5% in the past year, things are looking up for this mid-cap biotech company. With its latest medicine approval, Madrigal has successfully entered an underserved market and is ready to start reporting sales for the first time.On March 14th, the FDA gave the green light to Madrigal's Rezdiffra therapy, the first drug approved to treat metabolic dysfunction-associated steatohepatitis (MASH), which used to be known as non-alcoholic steatohepatitis (NASH).This drug got approved on an accelerated basis, so regulators are obviously confident in its effectiveness. With about 1.5 million Americans suffering from MASH, and the company's approved therapy able to treat about 315,00

图片Now, $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ are dominating the weight loss market, but a rising biotech star might just give them a run for their money. $Viking Therapeutics(VKTX)$ is a small but mighty biotech company, focused on developing treatments for metabolic and endocrine disorders. Many other pharma giants have tried and failed to break into this booming market, but Viking seems to be on the right track.Weeks ago, Viking announced positive results from the Phase II trial of its GLP-1 and GIP dual agonist, VK2735. The hype surrounding this obesity drug candidate has sent Viking's stock soaring!With this Phase II success, Viking has a few clear optio

图片In the past few years, $Novo-Nordisk A/S(NVO)$ has been on a roll in the capital markets, with its diabetes drug Ozempic and weight-loss drug Wegovy igniting a frenzy. Its stock price has skyrocketed 270% in the past three years. But now, the weight-loss stock is about to get even hotter with the arrival of its "third fire" - the oral weight-loss drug amycretin.Recent trial results for amycretin released by Novo Nordisk show that this experimental drug is even more effective than Ozempic and Wegovy in terms of weight loss. As a result, the company is considering skipping straight to phase three trials.If this plan pans out, it'll speed up the development and launch of amycretin. But let's be realistic - even if it does work, this weight-loss drug

图片Under the double pressure of falling COVID-19 sales and the patent cliff, $Pfizer(PFE)$ 's stock price has plunged more than 50% from its peak in late 2021 and over 30% in the past 12 months. Sales and profits have also taken a nosedive.Still, there are five reasons to buy the drugmaker right now.1.COVID-19 Has Hit BottomThe recent decline in Pfizer's stock price can largely be attributed to the decreasing demand for COVID-19 products, such as the Comirnaty vaccine and Paxlovid oral drug. Fortunately, the company's COVID-19 sales are expected to have bottomed out, greatly reducing inventory impairments and year-over-year performance pressure. Even better, the company expects to launch a combination COVID-flu vaccine in 2025, which could boost sal

The FDA has approved the first-ever treatment for a common and potentially fatal liver disease that affects millions of people worldwide.This FDA decision means that $Madrigal Pharmaceuticals(MDGL)$ has scored a major victory in a disease area where several big companies have failed or are still struggling to get in. Following the approval, Madrigal's stock price jumped over 20%.$Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ are testing their heavyweight weight-loss injections to treat nonalcoholic steatohepatitis (NASH).Madrigal's drug, to be marketed as Rezdiffra, is specifically designed for NASH patients with moderate to severe liver scarring. The FDA says this t